Share-based Payment Arrangement, Expense in USD of CRISPR Therapeutics AG from 2014 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
CRISPR Therapeutics AG quarterly/annual Share-based Payment Arrangement, Expense history and change rate from 2014 to Q3 2025.
  • CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $16.6M, a 22.9% decline year-over-year.
  • CRISPR Therapeutics AG Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $76.4M, a 8.03% decline year-over-year.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2024 was $86.6M, a 6.84% increase from 2023.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2023 was $81M, a 17.3% decline from 2022.
  • CRISPR Therapeutics AG annual Share-based Payment Arrangement, Expense for 2022 was $97.9M, a 4.34% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

CRISPR Therapeutics AG Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $76.4M $16.6M -$4.94M -22.9% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-10
Q2 2025 $81.3M $17.6M -$6.07M -25.6% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-04
Q1 2025 $87.4M $20.2M +$807K +4.16% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-06
Q4 2024 $86.6M $21.9M +$3.53M +19.1% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-11
Q3 2024 $83M $21.5M +$1.58M +7.89% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-10
Q2 2024 $81.5M $23.7M +$1.91M +8.76% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-04
Q1 2024 $79.6M $19.4M -$1.47M -7.04% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-06
Q4 2023 $81M $18.4M -$4.39M -19.2% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-11
Q3 2023 $85.4M $20M -$4.58M -18.6% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-05
Q2 2023 $90M $21.8M -$3.09M -12.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-05
Q1 2023 $93.1M $20.9M -$4.87M -18.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $97.9M $22.8M -$2.96M -11.5% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-11
Q3 2022 $101M $24.5M -$1.66M -6.32% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $103M $24.9M -$3.48M -12.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $106M $25.7M +$3.65M +16.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $102M $25.8M +$6.84M +36.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-21
Q3 2021 $95.6M $26.2M +$8.96M +52% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 $86.6M $28.3M +$12.6M +80.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $74M $22.1M +$7.94M +56.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $66M $18.9M +$7.07M +59.7% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $58.9M $17.2M +$2.47M +16.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-03
Q2 2020 $56.5M $15.7M +$3.5M +28.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $53M $14.2M +$3.46M +32.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $49.5M $11.9M -$2.19M -15.6% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-15
Q3 2019 $51.7M $14.8M +$5.71M +62.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-28
Q2 2019 $46M $12.2M +$2.72M +28.7% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-27
Q1 2019 $43.3M $10.7M +$4.02M +60.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-28
Q4 2018 $39.3M $14M +$6.61M +89% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-16
Q3 2018 $32.6M $9.07M +$3.84M +73.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-28
Q2 2018 $21.5M $9.48M +$5.25M +124% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-29
Q2 2018 $2.2M -$2.03M -48% May 1, 2018 May 31, 2018 10-Q 2018-08-07
Q1 2018 $23.6M $6.67M +$2.93M +78.1% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q4 2017 $20.6M $7.43M +$3.4M +84.5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-12
Q3 2017 $17.2M $5.23M +$2.93M +128% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $14.3M $4.23M +$730K +20.9% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 $13.6M $3.75M +$2.72M +267% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $10.8M $4.03M Oct 1, 2016 Dec 31, 2016 10-K 2019-02-25
Q3 2016 $2.29M +$1.26M +123% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q2 2016 $3.5M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-10
Q1 2016 $1.02M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-11
Q3 2015 $1.03M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-22

CRISPR Therapeutics AG Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $86.6M +$5.54M +6.84% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-11
2023 $81M -$16.9M -17.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-11
2022 $97.9M -$4.44M -4.34% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-11
2021 $102M +$36.4M +55.1% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 $66M +$16.5M +33.3% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-21
2019 $49.5M +$10.3M +26.1% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $39.3M +$18.6M +90.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-16
2017 $20.6M +$9.79M +90.3% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-12
2016 $10.8M +$7.16M +194% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-25
2015 $3.68M +$2.99M +430% Jan 1, 2015 Dec 31, 2015 10-K 2018-03-08
2014 $695K Jan 1, 2014 Dec 31, 2014 10-K 2017-03-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.